Episode 90: GSM Essentials for 2025: Top Treatment Updates, Safety Guidance, and Patient Impact

In this episode, Jillian Moehle focused on the latest evidence-based strategies for recognizing and treating Genitourinary Syndrome of Menopause (GSM). She explored newly updated guidelines from the American Urological Association, emphasizing the importance of proactive screening, a comprehensive approach to patient history, and the range of therapeutic options available, from non-hormonal treatments like moisturizers and lubricants, to hormone-based therapies including low-dose vaginal estrogen. Several points were raised, including safety considerations, the removal of the FDA black box warning on vaginal estrogen, and the crucial role of pelvic floor health in patient outcomes.Enroll now in: Under-Recognized, Under-Treated, and Misrepresented Realities of the Perimenopause and Menopause Transition, with Leslie Fuller, ND and Jillian Moehle, ND at https://pages.kharrazianinstitute.com/fuller-moehle-perimenopause00:00 Vaginal treatment recommendations and concerns05:26 Discussing hormone therapy alternatives08:13 Treatment options for vaginal health13:16 FDA removes black box warning15:24 Support for vaginal estrogen use18:13 Using GoodRx and applying cream22:00 Possible side effects and management24:54 Impact of GSM on women's health30:59 Podcast outro and resources sharingSupport this show http://supporter.acast.com/solving-the-puzzle-with-dr-datis-kharrazian. Hosted on Acast. See acast.com/privacy for more information.